Spravato® (esketamine) rejected by NICE for treatment-resistant depression

Written by Sharon Salt, Senior Editor

Earlier last year, the US FDA approved a new nasal spray antidepressant termed, Spravato® (esketamine), alongside an oral antidepressant for treatment-resistant depression in adults. However, the National Institute for Health and Care Excellence (NICE) has decided not to recommend the formulation over concerns regarding its clinical and cost–effectiveness. In response to this, Jennifer Lee (Director of Health Economics, Market Access and Reimbursement at Janssen [High Wycombe, UK]) issued a statement on NICE’s decision stating that: “This negative opinion from NICE is extremely disappointing as it is a decision which may potentially deny patients living with treatment-resistant major depressive disorder access...

To view the full article, please register now for access

It's completely free